Key facts
- This page summarizes John R. Wilson's Form 4 filing for Allovir, Inc. (KLRS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 May 2021, 16:50.
John R. Wilson - 25 May 2021 Form 4 Insider Report for Allovir, Inc. (KLRS)
- Reporting relationship
- Director
- Issuer ticker
- KLRS
- Reported as of
- 25 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 May 2021, 16:50:42 UTC
- Next SEC filing
- 10 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brett Hagen, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John R. Wilson filed Form 4 for Allovir, Inc. (KLRS) on 27 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALVR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,197,999
- Date
- 25 May 2021
- Ownership
- See footnote
- Footnotes
- F1, F2
ALVR
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,164,954
- Date
- 25 May 2021
- Ownership
- See footnote
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALVR
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +22,500
- Change %
- Price
- $0.000000
- Shares after
- 22,500
- Date
- 25 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,500
- Exercise price
- $21.51
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Previous Section 16 reports filed by the Reporting Person have inadvertently reported certain shares of common stock as being held through multiple forms of indirect ownership. This report serves to correct and clarify that (a) 2,197,999 shares are held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020 and (b) 3,164,954 shares are held by John R. Wilson, as trustee of the John R. Wilson Revocable Trust Agreement dated August 3, 2017.
Footnote F2
Shares held by Meristem Trust Company, LLC as trustee of the John R. Wilson Irrevocable Trust dated July 9, 2020, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Footnote F3
Shares held by the Reporting Person as Trustee of the John R. Wilson Revocable Trust Agreement dated August 3, 2017. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Footnote F4
This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders.